Interstitial lung disease
MONDO:0015925A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of pulmonary alveoli that extends to the interstitium and beyond leading to diffuse pulmonary fibrosis. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
Also known as: ILD, interstitial lung disease
659 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could a second dose of steroids help premature babies breathe easier?
Disease control TerminatedThis study investigates whether giving a repeat course of betamethasone, a steroid, to pregnant women with preterm premature rupture of membranes (PPROM) can improve health outcomes for their premature babies. The main goal is to see if it shortens the baby's stay in the neonatal…
Phase: PHASE2, PHASE3 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Rollover study offers continued itacitinib access for chronic disease patients
Disease control TerminatedThis study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as …
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental drug aims to help COVID survivors breathe easier
Disease control TerminatedThis study tested a drug called deupirfenidone (LYT-100) in 185 adults who had breathing problems after a serious COVID-19 infection. Participants took either the drug or a placebo for several weeks to see if it improved their ability to walk. The trial was stopped early, so the …
Phase: PHASE2 • Sponsor: PureTech • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
COVID-19 drug trial halted early: only 16 patients enrolled
Disease control TerminatedThis study tested an experimental drug called APX-115 in hospitalized patients with mild to moderate COVID-19. The goal was to see if it was safe and could help people recover faster. However, the trial was stopped early and only 16 people took part, so we don't have enough infor…
Phase: PHASE2 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Inhaled drug aims to save transplanted lungs from silent threat
Disease control TerminatedThis study tested an inhaled form of cyclosporine A (L-CsA) added to standard care for lung transplant patients with bronchiolitis obliterans syndrome (BOS), a condition that scars the lungs' small airways. The goal was to see if the treatment could slow the decline in lung funct…
Phase: PHASE3 • Sponsor: Zambon SpA • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug hope for lung damage after transplant falls short
Disease control TerminatedThis study tested the drug ruxolitinib to treat early lung damage in children and adults who had a stem cell transplant. Lung problems like bronchiolitis obliterans can be serious and hard to detect early. The trial aimed to see if adding ruxolitinib to standard care could improv…
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for lung scarring? trial of GSK3915393 cut short
Disease control TerminatedThis study tested a new medicine, GSK3915393, in 158 people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. The goal was to see if the drug could slow lung function decline compared to a placebo. The trial was termin…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental drug vixarelimab tested for two scarring lung diseases
Disease control TerminatedThis study tested the drug vixarelimab against a placebo in people with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-associated interstitial lung disease (SSc-ILD). The goal was to see if it could preserve lung function over 52 weeks. The trial was terminated early, …
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Lung fibrosis drug study halted early
Disease control TerminatedThis study tested new single treatments for idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. It included 46 adults aged 40 and older with mild to moderate IPF. The main goal was to see if the treatments improved lung function, mea…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a drug make milk allergy therapy safer and more effective?
Disease control TerminatedThis study tested whether adding dupilumab (a drug that reduces allergic reactions) to milk oral immunotherapy (gradually eating small amounts of milk) helps people with cow's milk allergy tolerate more milk with fewer side effects. The trial included 33 people aged 4 to 50 years…
Phase: PHASE2 • Sponsor: Andrew J Long, PharmD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Promising IPF drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called HZN-825 in people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. The trial aimed to see if the drug could slow the decline in lung function over a year. About 153 adults with IP…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Lung disease drug trial in kids halted early
Disease control TerminatedThis study tested whether hydroxychloroquine could help children with a rare lung condition called interstitial lung disease. About 35 children were planned to take either the drug or a placebo to see if their oxygen levels or breathing improved. The trial was stopped early, so r…
Phase: PHASE2 • Sponsor: Matthias Griese • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental drug tested for rare lung condition after transplant
Disease control TerminatedThis early-stage study tested the safety of a drug called itacitinib in 8 adults who developed bronchiolitis obliterans syndrome (a type of lung scarring) after receiving a stem cell transplant from a donor. The goal was to see if the drug could help control the lung disease by b…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental drug itacitinib tested for lung transplant complication – study stopped early
Disease control TerminatedThis early-phase trial tested the drug itacitinib in 23 people who developed bronchiolitis obliterans syndrome (a type of chronic lung rejection) after a double lung transplant. The goal was to see if itacitinib could safely improve lung function. However, the study was terminate…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Inhaler trial for Kids' lung decline after transplant ends early
Disease control TerminatedThis phase 3 trial tested whether a combination inhaler (fluticasone and salmeterol) could improve lung function in children aged 6–17 who had a drop in breathing capacity after a stem cell transplant. The study aimed to prevent bronchiolitis obliterans, a serious lung complicati…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 17:44 UTC
-
New drug namilumab tested for lung sarcoidosis – but trial halted early
Disease control TerminatedThis study tested namilumab, an experimental drug, in 107 people with chronic pulmonary sarcoidosis, a condition causing lung inflammation. The trial was randomized and placebo-controlled, but it was terminated early. The goal was to see if namilumab could reduce the need for res…
Phase: PHASE2 • Sponsor: Kinevant Sciences GmbH • Aim: Disease control
Last updated Jun 26, 2026 15:32 UTC
-
Lung disease drug tested in rare muscle condition – trial cut short
Disease control TerminatedThis study tested the drug nintedanib (Ofev) in 11 people with myositis-related interstitial lung disease, a condition where lung scarring occurs alongside muscle inflammation. The goal was to see if the drug is safe and tolerable when added to standard immune-suppressing treatme…
Phase: NA • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC
-
Sarcoidosis drug study halted after only 2 patients enrolled
Symptom relief TerminatedThis study tested whether Acthar gel could improve symptoms and lung function in people with sarcoidosis, a disease that causes inflammation in the lungs. Researchers also checked if a blood marker called CXCL9 could predict how well the treatment works. Only 2 people joined befo…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 12:27 UTC
-
New pill aims to quiet debilitating cough in lung scarring disease
Symptom relief TerminatedThis study tested an experimental drug called BI 1839100 in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) who have a chronic cough. Participants took different doses of the drug or a placebo for 12 weeks. The goal was to see if the drug c…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Musical pacifier may help preemies with lung disease eat sooner
Symptom relief TerminatedThis study tested a special pacifier that plays music or a mother's voice when a baby sucks correctly. It aimed to help premature infants with chronic lung disease learn to feed by mouth more quickly. The trial enrolled 33 babies but was stopped early, so the results are not conc…
Phase: NA • Sponsor: University of Missouri-Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
New study tracks lung function and symptoms in fibrosis patients on nintedanib
Knowledge-focused TerminatedThis study looked at 88 adults with connective tissue disease-related lung scarring who were prescribed nintedanib. Researchers measured changes in lung function and tracked cough and breathlessness using a questionnaire over 24 months. The goal was to see if improvements in lung…
Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lung cancer study aims to predict dangerous lung inflammation
Knowledge-focused TerminatedThis study followed 83 people with advanced non-small cell lung cancer who were starting standard treatments. The goal was to collect information to help develop a digital tool that can spot early signs of pneumonitis/ILD, a serious lung inflammation that can occur as a side effe…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New lung camera could replace needle biopsies
Knowledge-focused TerminatedThis study aimed to see if a tiny camera on a thin tube (bronchoscopy) could help doctors diagnose diffuse lung diseases without needing a surgical lung biopsy. The camera takes live microscopic images of the air sacs. The study was stopped early, but it involved 38 adults with c…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Sleep apnea machine tested for IPF lung health – but study stopped early
Knowledge-focused TerminatedThis study looked at whether using a CPAP machine at night could reduce abnormal acid reflux and lung inflammation in people with idiopathic pulmonary fibrosis (IPF) who also have sleep apnea. Only 7 people enrolled before the study was terminated early. The goal was to measure c…
Phase: NA • Sponsor: University of Arizona • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Tiny study on lung support in ARDS halted early
Knowledge-focused TerminatedThis study aimed to compare two ways of setting breathing machine pressure (PEEP) in patients with severe lung injury (ARDS). The goal was to see which method better protects the lungs and heart. Only 2 patients were enrolled before the study was stopped, so no meaningful results…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
AI stethoscope could spot lung disease patterns
Knowledge-focused TerminatedThis study tested whether artificial intelligence can detect and classify abnormal lung sounds in people with cystic fibrosis, COPD, or pulmonary fibrosis. Researchers recorded lung sounds with an electronic stethoscope during routine checkups and analyzed them using AI. The goal…
Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Breathing in a special gas reveals hidden lung damage in transplant patients
Knowledge-focused TerminatedThis study used a special MRI technique with a harmless gas called hyperpolarized xenon-129 to take detailed pictures of lung function in people who had a lung transplant. The goal was to see if this scan could detect early signs of chronic lung allograft dysfunction (CLAD), a co…
Sponsor: Xemed LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Tiny study on drug monitoring in scleroderma ends early
Knowledge-focused TerminatedThis study aimed to see if measuring the amount of mycophenolic acid in the blood could help doctors adjust the dose of mycophenolate mofetil (MMF) to better treat skin and lung problems in people with systemic sclerosis. Only 2 patients were enrolled before the study was termina…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:32 UTC
-
Xenon gas MRI could spot lung transplant rejection early
Knowledge-focused TerminatedThis study tested a new type of MRI that uses inhaled xenon gas to create detailed images of the lungs. The goal was to see if it could detect early signs of chronic rejection in lung transplant recipients. Only 6 adults who had double lung transplants took part, and the study wa…
Phase: PHASE2 • Sponsor: The Hospital for Sick Children • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:27 UTC